全文获取类型
收费全文 | 218499篇 |
免费 | 20102篇 |
国内免费 | 9837篇 |
专业分类
耳鼻咽喉 | 2894篇 |
儿科学 | 5138篇 |
妇产科学 | 2773篇 |
基础医学 | 35563篇 |
口腔科学 | 6283篇 |
临床医学 | 17802篇 |
内科学 | 27087篇 |
皮肤病学 | 5043篇 |
神经病学 | 11491篇 |
特种医学 | 6679篇 |
外国民族医学 | 159篇 |
外科学 | 21123篇 |
综合类 | 34987篇 |
现状与发展 | 61篇 |
预防医学 | 5829篇 |
眼科学 | 4019篇 |
药学 | 16355篇 |
65篇 | |
中国医学 | 6686篇 |
肿瘤学 | 38401篇 |
出版年
2024年 | 316篇 |
2023年 | 3020篇 |
2022年 | 4087篇 |
2021年 | 8152篇 |
2020年 | 7145篇 |
2019年 | 6771篇 |
2018年 | 6835篇 |
2017年 | 7372篇 |
2016年 | 7928篇 |
2015年 | 8897篇 |
2014年 | 13103篇 |
2013年 | 14178篇 |
2012年 | 12423篇 |
2011年 | 13876篇 |
2010年 | 11452篇 |
2009年 | 11156篇 |
2008年 | 11622篇 |
2007年 | 11981篇 |
2006年 | 10942篇 |
2005年 | 9958篇 |
2004年 | 8735篇 |
2003年 | 7541篇 |
2002年 | 6376篇 |
2001年 | 5549篇 |
2000年 | 4565篇 |
1999年 | 4120篇 |
1998年 | 3779篇 |
1997年 | 3475篇 |
1996年 | 3120篇 |
1995年 | 2727篇 |
1994年 | 2398篇 |
1993年 | 1955篇 |
1992年 | 1596篇 |
1991年 | 1478篇 |
1990年 | 1141篇 |
1989年 | 1068篇 |
1988年 | 1000篇 |
1987年 | 816篇 |
1986年 | 724篇 |
1985年 | 954篇 |
1984年 | 862篇 |
1983年 | 583篇 |
1982年 | 637篇 |
1981年 | 510篇 |
1980年 | 416篇 |
1979年 | 338篇 |
1978年 | 230篇 |
1977年 | 182篇 |
1976年 | 138篇 |
1975年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
141.
142.
免疫检查点抑制剂已经改变了包括肺癌、黑色素瘤等许多肿瘤的治疗情况,并且在一些难治性肿瘤中表现出持久的应答率,然而在部分接受治疗的患者中表现出无反应及严重免疫相关副作用。为了优化免疫疗法的使用,可能需要多种临床应答的预测性标志物。本研究回顾了几种潜在有效生物标志物的可用数据,通过免疫组化检测肿瘤细胞和免疫细胞中PD-L1的表达,提示其是一种临床疗效的良好预测标志物;且PD-L1表达阴性者经免疫治疗后仍可获益。PD-L1表达在肿瘤内是动态和异质性的:在原发性灶和转移灶之间或在穿刺标本和大体标本之间表达不一致。肿瘤突变负荷与新抗原的高比率可获得持久获益。外周血标志物也可作为潜在标志物,增加的绝对淋巴细胞计数(ALC)与疾病控制和生存显著相关。在这篇综述中,我们旨在讨论抗PD-(L)1与抗CTLA-4 免疫治疗相关标志物研究现状,为临床运用提供指导,以便能够准确筛选出从这些治疗中获益更多的患者。 相似文献
143.
《Clinical genitourinary cancer》2020,18(1):56-61
BackgroundClear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC.Materials and MethodsSingle nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.ResultsChromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).ConclusionsChromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC. 相似文献
144.
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth
factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib
monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily
pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective
analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib
(250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second or
more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response
rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival
(mOS), and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with
adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The
mPFS and mOS were 4.93 (range, 0.27−32.91; 95% CI 3.64−6.22) and 14.70 (range, 0.27−32.91; 95% CI
0.27−43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the
entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients
who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable
mPFS (11.77 vs. 2.27 months, p<0.05) and mOS (24.03 vs. 6.07 months, p<0.05). Treatment-related toxicities
were tolerable including grade 1/2 hypertension, hand-and-foot syndrome, fatigue, nausea, liver dysfunction,
myelosuppression, skin rash, and palpitation. In conclusion, apatinib exhibited high activity and good tolerance
for NSCLC patients with brain metastasis, and it might become a potential choice for metastatic brain tumors
in NSCLC patients. 相似文献
145.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
146.
Taisuke Inada Satoshi Fukushima Masayuki Murai Masatoshi Jinnin Azusa Miyashita Satoshi Nakahara Junji Yamashita Jun Aoi Shinichi Masuguchi Hironobu Ihn 《The Journal of dermatology》2015,42(2):198-201
miRNA‐221 (miR‐221) is known to be abnormally expressed in many human cancers. The serum levels of miR‐221 have been reported as a tumor marker for malignant melanoma (MM). We hypothesized that the hair shaft miR‐221 levels may be increased in patients with MM. We therefore assessed the possibility that hair shaft miR‐221 levels could be a marker for MM. The hair shaft miR‐221 levels were significantly higher in patients with MM than controls. The rates of increased hair shaft miR‐221 levels above the cut‐off value were comparable to those of serum 5‐S‐CD, which is a tumor marker commonly used for MM. Measurements of the hair shaft miR‐221 levels could have potential clinical value in the detection of MM. This is the first report investigating the hair shaft levels of an miRNA in patients with MM. Our investigations offer new insight into the relationship between miR‐221 and MM, and may provide a new, non‐invasive way to screen for melanoma. 相似文献
147.
张献彩 《山西医科大学学报》2015,(1)
目的:观察糖尿病小鼠小肠绒毛杯状细胞分泌的黏原颗粒是否改变,为进一步研究糖尿病的消化系统并发症提供形态学基础。方法分别选取3,5,8,10月龄db/db糖尿病小鼠及相应年龄段的db/+m正常小鼠,每组6只,标本用4%多聚甲醛灌流固定后,从距Treitz韧带约10 cm处切下一段空肠,用PAS染色方法对小肠杯状细胞分泌的黏原颗粒进行观察。结果糖尿病组小肠绒毛易被破坏,糖尿病组中杯状细胞的分泌物比同月份正常对照组显著增加(P<0.05);糖尿病组中3月龄的杯状细胞分泌物最多,8月龄最少,并且8月龄分别与3月龄、5月龄比较均存在着显著差异(P<0.05);正常对照组随月龄增长无显著性差异(P>0.05)。结论糖尿病时杯状细胞分泌物增多可能对小肠绒毛有保护作用。 相似文献
148.
《Cancer cell》2021,39(11):1497-1518.e11
149.
150.
随着对肿瘤热疗和肿瘤免疫微环境(TIME)的深入研究,近年来热疗对TIME的作用越来越受到学者们的重视。本文就目前国内外研究进展,对热疗与TIME中几类主要免疫细胞和免疫相关细胞因子的影响及作用机制作一综述。全面而透彻的了解热疗对TIME的调控作用,有助于为肿瘤治疗提供新的思路和方法。 相似文献